Home › Therapeutic areas › Neurology › Huntington's Disease

Huntington's Disease (6 companies)

Companies with an active program in Huntington's Disease.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $662M 6
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $4.49B 29
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $207M 13
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 2 Approved $1.58B 11
QURE uniQure HematologyMetabolic+1 Rare 1 Approved $1.46B 4
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $560M 5